DAVID
LORA PABLOS
Investigador ata 2024
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (11)
2024
2022
-
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
eClinicalMedicine, Vol. 50
-
Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
Trials, Vol. 23, Núm. 1
2021
-
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
The Lancet, Vol. 398, Núm. 10295, pp. 121-130
2017
-
Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11
2016
-
Propensity score analysis of the role of initial antifungal therapy in the outcome of Candida glabrata bloodstream infections
Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 6, pp. 3291-3300
2014
-
Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: A propensity score analysis
Clinical Infectious Diseases, Vol. 58, Núm. 10, pp. 1413-1421
-
Validation of a prognostic score for early mortality in severe head injury cases
Journal of Neurosurgery, Vol. 121, Núm. 6, pp. 1314-1322
2013
-
Necessary resources and barriers perceived by professionals in the implementation of the NIDCAP
Early Human Development, Vol. 89, Núm. 9, pp. 649-653
2009
-
Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor α therapy in rheumatoid arthritis
Annals of the Rheumatic Diseases, Vol. 68, Núm. 5, pp. 751-756
2008
-
Gestational diabetes mellitus in a cohort of HIV-1 infected women
HIV Medicine, Vol. 9, Núm. 10, pp. 868-874